In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and Exposition which assessed a triplet nonchemotherapy regimen in older and medically unfit patients with ...

A 2025 report cowritten by Iyengar that quoted federal data, said that the 5-year DLBCL survival is approximately 80% in ...

Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), ...

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL.

Palliative care for diffuse large B-cell lymphoma has significantly improved over the past several years, but disparities ...

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

Doctors may not need to avoid steroids before biopsy in patients with a common aggressive lymphoma, according to a new study.

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

—This large, population-based study of patients with PP-DLBCL assessed prognostic factors and confirmed that certain common therapeutic interventions can modify disease progression. Being age 65 years ...